Perrigo PE Ratio 2010-2025 | PRGO
Current and historical p/e ratio for Perrigo (PRGO) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Perrigo PE ratio as of July 04, 2025 is 9.48.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Perrigo PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-07-03 | 27.20 | 0.00 | |
| 2025-03-31 | 27.74 | $-1.31 | 0.00 |
| 2024-12-31 | 25.18 | $-1.25 | 0.00 |
| 2024-09-30 | 25.44 | $-1.17 | 0.00 |
| 2024-06-30 | 24.67 | $-0.92 | 0.00 |
| 2024-03-31 | 30.62 | $-0.07 | 0.00 |
| 2023-12-31 | 30.31 | $-0.10 | 0.00 |
| 2023-09-30 | 29.82 | $0.05 | 596.36 |
| 2023-06-30 | 31.44 | $-0.42 | 0.00 |
| 2023-03-31 | 32.94 | $-0.96 | 0.00 |
| 2022-12-31 | 31.07 | $-0.96 | 0.00 |
| 2022-09-30 | 32.24 | $-0.63 | 0.00 |
| 2022-06-30 | 36.43 | $-0.70 | 0.00 |
| 2022-03-31 | 34.28 | $-0.65 | 0.00 |
| 2021-12-31 | 34.44 | $-0.35 | 0.00 |
| 2021-09-30 | 41.63 | $-1.88 | 0.00 |
| 2021-06-30 | 40.09 | $-2.57 | 0.00 |
| 2021-03-31 | 35.20 | $-1.70 | 0.00 |
| 2020-12-31 | 38.68 | $-1.21 | 0.00 |
| 2020-09-30 | 39.52 | $-0.06 | 0.00 |
| 2020-06-30 | 47.37 | $1.74 | 27.23 |
| 2020-03-31 | 41.05 | $1.37 | 29.96 |
| 2019-12-31 | 43.94 | $1.07 | 41.06 |
| 2019-09-30 | 47.34 | $1.81 | 26.15 |
| 2019-06-30 | 40.15 | $0.65 | 61.77 |
| 2019-03-31 | 40.42 | $0.84 | 48.12 |
| 2018-12-31 | 32.39 | $0.94 | 34.46 |
| 2018-09-30 | 59.00 | $0.86 | 68.61 |
| 2018-06-30 | 60.60 | $1.66 | 36.51 |
| 2018-03-31 | 69.10 | $0.91 | 75.94 |
| 2017-12-31 | 72.10 | $0.84 | 85.83 |
| 2017-09-30 | 69.90 | $-9.16 | 0.00 |
| 2017-06-30 | 62.23 | $-18.23 | 0.00 |
| 2017-03-31 | 54.59 | $-16.39 | 0.00 |
| 2016-12-31 | 68.29 | $-19.23 | 0.00 |
| 2016-09-30 | 75.63 | $-10.49 | 0.00 |
| 2016-06-30 | 74.15 | $-0.96 | 0.00 |
| 2016-03-31 | 104.47 | $-1.93 | 0.00 |
| 2015-12-31 | 118.03 | $-0.26 | 0.00 |
| 2015-09-30 | 128.17 | $0.99 | 129.46 |
| 2015-06-30 | 150.52 | $0.94 | 160.13 |
| 2015-03-31 | 134.74 | $0.56 | 240.60 |
| 2014-12-31 | 135.94 | $1.59 | 85.49 |
| 2014-09-30 | 122.05 | $0.21 | 581.21 |
| 2014-06-30 | 118.37 | $0.67 | 176.67 |
| 2014-03-31 | 125.50 | $0.67 | 187.31 |
| 2013-12-31 | 124.45 | $1.49 | 83.52 |
| 2013-09-30 | 99.99 | $3.48 | 28.73 |
| 2013-06-30 | 97.98 | $3.42 | 28.65 |
| 2013-03-31 | 96.08 | $3.42 | 28.09 |
| 2012-12-31 | 84.11 | $3.47 | 24.24 |
| 2012-09-30 | 93.84 | $3.41 | 27.52 |
| 2012-06-30 | 95.20 | $3.04 | 31.31 |
| 2012-03-31 | 83.33 | $3.04 | 27.41 |
| 2011-12-31 | 78.42 | $2.76 | 28.41 |
| 2011-09-30 | 78.20 | $2.67 | 29.29 |
| 2011-06-30 | 70.70 | $2.72 | 25.99 |
| 2011-03-31 | 63.93 | $2.72 | 23.50 |
| 2010-12-31 | 50.87 | $2.43 | 20.93 |
| 2010-09-30 | 51.52 | $2.01 | 25.63 |
| 2010-06-30 | 47.34 | $1.87 | 25.32 |
| 2010-03-31 | 47.01 | $1.87 | 25.14 |
| 2009-12-31 | 31.84 | $1.70 | 18.73 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.739B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $233.904B | 28.13 |
| Boston Scientific (BSX) | United States | $154.336B | 38.64 |
| Stryker (SYK) | United States | $150.874B | 31.55 |
| EssilorLuxottica (ESLOY) | France | $127.819B | 0.00 |
| Medtronic (MDT) | Ireland | $113.364B | 16.07 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.609B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.066B | 26.28 |
| ResMed (RMD) | United States | $37.677B | 28.30 |
| GE HealthCare Technologies (GEHC) | United States | $34.831B | 16.54 |
| Agilent Technologies (A) | United States | $34.480B | 22.48 |
| Terumo (TRUMY) | Japan | $25.244B | 32.79 |
| Koninklijke Philips (PHG) | Netherlands | $23.274B | 16.33 |
| Insulet (PODD) | United States | $21.186B | 83.16 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.532B | 11.90 |
| Baxter (BAX) | United States | $15.914B | 11.88 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.262B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.846B | 23.82 |
| Lantheus Holdings (LNTH) | United States | $5.564B | 14.03 |
| Prestige Consumer Healthcare (PBH) | United States | $3.952B | 17.66 |
| Haemonetics (HAE) | United States | $3.693B | 16.82 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.456B | 28.72 |
| ICU Medical (ICUI) | United States | $3.333B | 24.58 |
| QuidelOrtho (QDEL) | United States | $2.042B | 14.04 |
| LeMaitre Vascular (LMAT) | United States | $1.907B | 42.62 |
| AtriCure (ATRC) | United States | $1.572B | 0.00 |
| Acuren (TIC) | United States | $1.378B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.258B | 12.77 |
| Green Thumb Industries (GTBIF) | United States | $1.164B | 26.19 |
| Neogen (NEOG) | United States | $1.157B | 14.81 |
| Phibro Animal Health (PAHC) | United States | $1.135B | 14.51 |
| BioLife Solutions (BLFS) | United States | $1.085B | 0.00 |
| InMode (INMD) | Israel | $0.958B | 9.66 |
| Kestra Medical Technologies (KMTS) | United States | $0.805B | 0.00 |
| Owens & Minor (OMI) | United States | $0.712B | 5.90 |
| CeriBell (CBLL) | United States | $0.684B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.680B | 0.00 |
| Evolus (EOLS) | United States | $0.598B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.555B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.542B | 0.00 |
| Valneva SE (VALN) | France | $0.494B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.468B | 0.00 |
| Surmodics (SRDX) | United States | $0.429B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.363B | 13.33 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.360B | 0.00 |
| Quanterix (QTRX) | United States | $0.349B | 0.00 |
| SNDL (SNDL) | Canada | $0.334B | 0.00 |
| Cerus (CERS) | United States | $0.294B | 0.00 |
| ZimVie (ZIMV) | United States | $0.285B | 12.97 |
| Viemed Healthcare (VMD) | United States | $0.283B | 23.83 |
| Sanuwave Health (SNWV) | United States | $0.271B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.264B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.255B | 75.67 |
| Brainsway (BWAY) | Israel | $0.250B | 66.20 |
| Cresco Labs (CRLBF) | United States | $0.246B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.235B | 0.00 |
| Biote (BTMD) | United States | $0.231B | 6.49 |
| OraSure Technologies (OSUR) | United States | $0.230B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.192B | 0.00 |
| Organigram Global (OGI) | Canada | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.190B | 15.46 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Omeros (OMER) | United States | $0.188B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.177B | 0.00 |
| Exagen (XGN) | United States | $0.150B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.144B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.133B | 16.35 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.097B | 12.48 |
| MacroGenics (MGNX) | United States | $0.092B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Veru (VERU) | United States | $0.089B | 0.00 |
| Apyx Medical (APYX) | United States | $0.087B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.084B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.077B | 0.00 |
| Zynex (ZYXI) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.068B | 0.00 | |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 57.57 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.86 |
| Safety Shot (SHOT) | United States | $0.030B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.028B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |